NCT01456078已完成2 期
A Multicenter Phase II-Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Objective tumor response after a cumulative kidney biologically effective dose (BED) of 27 +/- 2 Gy
研究概览
简要总结
By improved kidney dosimetry including biological effective dose and taking into account potential risk factors (especially for kidney toxicity), it might be possible to give an optimal and personalized treatment with 177Lu-DOTA-TATE to the patient with metastatic neuroendocrine tumor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically verified neuroendocrine tumors with a Ki67 of at least 20 % or at least 20 mitoses/high power fields. If the tissue on which this determination is based is several years old, the investigator should consider the option of acquiring a new determination, especially if the behaviour of the tumor has changed since diagnosis
- •Metastatic disease where complete resection is not considered possible or feasible
- •Measurable disease
- •Radiological disease progression during the last 14 months
- •The largest metastases should have an uptake of 111In-octreotide that is greater than the uptake in the liver by planar scintigraphy. Metastases that are small, or located centrally, can be evaluated by SPECT to enable a correct estimation of the relative uptake. The majority of the tumor burden must demonstrate an increased uptake for lutetium-treatment to be considered
- •Stable dose of somatostatin analogue for the past 3 months
- •Estimated survival more than 6 months
- •ANC more than 1.5 x 10 9/L
- •Bilirubin less than 1.5 x upper limit of normal
- •GFR more than 50 ml/min.
- •Signed written informed concent
- •Continues to fulfill all of the inclusion criteria, and none of the exclusion criteria, from step 1
- •A maintained GFR (less than 40 % decrease compared to baseline AND GFR more than 50 ml/min)
- •The treatment in step 1 have been administered with a maximal interval of 12 weeks
- •Age under 70 years
排除标准
- •Performance Status ECOG 3-4
- •Proliferation index (Ki67) more than 20 % or more than 20 mitoses/hpf
- •Loco-regional treatment during the last 3 months involving all of the measurable lesions
- •Chemotherapy during the last 3 months, or longer if persisting toxicity exists. Earlier treatment with mTORi or TKI is permitted
- •Other concommitant nephrotoxic treatment
- •Modifications of the somatostatine dose in the last 3 months
- •Serious heart disease
- •Previous radiotherapy including more than 25 % of active bone marrow volume
- •Pregnancy and lactation
- •Extensive liver metastases (more than 50 % of liver volume)
- •Symptomatic CNS metastases requiring corticosteroid treatment
- •Ongoing treatment with interferon. This treatment should be suspended a minimum of 4 weeks before treatment with 177Lu-DOTA-TATE, or longer if there is persisting signs of toxicity
- •Patients who have another metastatic tumor diagnosis
- •Progressive disease since start of study treatment
- •Organ toxicity grade 3-4 during step 1
- •Serious hematological toxicity during previous treatment cycles (ANC less than 0.5 x 10 9 or platelets less than 50.0 x 10 9)
- •Longstanding diabetes (more than 8 years). Patients with a well-controlled diabetes with a history of less than 8 years and a blood pressure less than 130/80 and no albuminuria (albumin/creatinine index)can be included
- •Hypertension, i.e. more than 160/90 (for diabetics more than 130/80). Antihypertensive pharmacological treatment is permitted as long as there is no manifest albuminuria
- •Previous liver embolisation
- •Previous chemotherapy
研究组 & 干预措施
177Lu-DOTA-TATE
Experimental
干预措施: 177Lu-DOTA-TATE (Drug)
结局指标
主要结局
Objective tumor response after a cumulative kidney biologically effective dose (BED) of 27 +/- 2 Gy
时间窗: 3 months after completed step 1
次要结局
- Objective tumor response after receiving a cumulative BED to the kidneys of 40 +/- 2 Gy as per RECIST v 1.1(3 months after completing step 2 treatment)
研究者
研究点 (2)
Loading locations...
相似试验
撤回
2 期
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).Iron Deficiency AnemiaNCT05927012Keros Therapeutics, Inc.
已完成
2 期
Neuropathic Pain in Patients With CancerNeuropathic PainNCT00474916DARA Therapeutics19
已完成
2 期
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Chronic Lymphocytic LeukemiaNCT00963105Celgene104
已完成
2 期
Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes SubjectsType 2 Diabetes MellitusNCT03406377OPKO Health, Inc.113
已完成
2 期
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)MigraineNCT01613248Allergan834